Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 19, 2017CSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn StateCSL Behring commits $4.92 million to Penn State's multidisciplinary Center of Excellence in Biotechnology
19 Sep 2017 UNIVERSITY PARK, Pa. — 19 September 2017 Penn State today announced that CSL Behring a global specialty biotherapeutics leader, has committed $4.92 million to Penn State over the...
-
Sep 14, 2017Immunoglobulin Leader Donates €15,000 to International Patient Organisation to Support Primary Immunodeficiency Awareness Initiatives
14 Sep 2017 EDINBURGH, UK — 14 September 2017 Global biotherapeutics leader CSL Behring today announced that its “Join Together” campaign at the 2017 European Society for Immunodeficiencies...
-
Sep 14, 2017Privigen shown to improve functional abilities in patients with a rare neurological condition
14 Sep 2017 KING OF PRUSSIA, Pa. — 14 September 2017 Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved Privigen® [Immune...
-
Sep 7, 2017- Symposium “Transitioning Clinical Data into Patient Care – Recent Real-Life Experiences with Alpha 1” - RAPID and RAPID extension trial data to be featured in poster and oral presentations
07 Sep 2017 MARBURG, Germany — 07 September 2017 Global biotherapeutics leader CSL Behring will host a symposium about Alpha 1 Antitrypsin Deficiency (AATD) on Monday, 11 September, during the...
-
Sep 6, 2017Biotherapeutics leader to map attendee visits to result in a donation to International Patient Organisation for Primary Immunodeficiencies (IPOPI)
06 Sep 2017 EDINBURGH, Scotland — 06 September 2017 Global biotherapeutics leader CSL Behring today announced that as part of its participation as a platinum sponsor of the 2017 meeting of the...
-
Aug 8, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Aug 7, 2017
Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase...
-
Jul 25, 2017- First and only subcutaneous preventive treatment option reduced HAE attacks by 95 percent (median) in treated patients - Comprehensive support program offered to patients
25 Jul 2017 KING OF PRUSSIA, Pa. — 25 July 2017 Global biotherapeutics leader CSL Behring today announced today that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) is now available in...
-
Jul 21, 2017FDA grants seven-year marketing exclusivity for subcutaneous C1-INH to prevent HAE attacks
21 Jul 2017 KING OF PRUSSIA, Pa. — 21 July 2017 Global biotherapeutics leader CSL Behring today announced today that the U.S. Food and Drug Administration (FDA) has granted the Company seven...
-
Jul 21, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jul 20, 2017
Seqirus is now shipping its portfolio of over 50 million doses of influenza vaccines to the U.S. market in preparation for the upcoming 2017-2018 influenza season. 20 Jul 2017 Seqirus is now...
-
Jul 19, 2017For the treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.
19 Jul 2017 KING OF PRUSSIA, Pa. — 19 July 2017 Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s...
-
Jul 18, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jul 12, 2017Findings presented at the International Society on Thrombosis and Haemostasis Congress 2017 show product’s impact on treatment adherence, consumption and quality of life
12 Jul 2017 BERLIN — 12 July 2017 CSL Behring today presented data finding that prophylaxis treatment with IDELVION® provides consistently high factor IX levels, resulting in low bleeding rates...
-
Jul 12, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jul 11, 2017CIDP and Autoimmune Epilepsy Researchers Granted 2017 Interlaken Leadership Awards
11 Jul 2017 SITGES, Spain — 11 July 2017 Global biotherapeutics leader CSL Behring today announced at the Peripheral Nerve Society’s annual meeting the winners of its annual Interlaken...
-
Jul 10, 2017Results of study, which compared AFSTYLA to octocog alfa, were presented at the International Society on Thrombosis and Haemostasis Congress 2017
10 Jul 2017 BERLIN — 10 July 2017 CSL Behring today presented data finding treatment with AFSTYLA® may result in low average product consumption without compromising efficacy in both the...
-
Jul 6, 2017New findings demonstrate CSL Behring’s promise to develop and deliver innovative treatments that improve patients’ lives
06 Jul 2017 MARBURG, Germany. — 06 July 2017 CSL Behring announced today that it will present new data from its recombinant coagulation factor development programs at the International Society...
-
Jun 23, 2017- HAEGARDA has been shown to reduce HAE attacks by 95 percent (median) in patients with a life-threatening, rare genetic disorder - Use of rescue medication was reduced by greater than 99 percent (1) - Subcutaneous administration builds and maintains steady-state C1-INH levels
23 Jun 2017 KING OF PRUSSIA, Pa. — 23 June 2017 Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved HAEGARDA® (C1 Esterase...
-
Jun 21, 2017
In an industry first, Seqirus has successfully produced cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather...
-
Jun 9, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jun 1, 2017
Australia’s biomedical researchers are invited to apply for one of two CSL Centenary Fellowships each worth $1.25million over five years in support of discovery and translational medical...
-
May 19, 2017Driven by its promise to save lives and protect people’s health, CSL Behring is honoured to be recognized by NORD, a tireless advocate for rare disease patients.
19 May 2017 KING OF PRUSSIA, Pa. — 19 May 2017 CSL Behring received the National Organization for Rare Disorders’ (NORD) 2017 Industry Innovation Award last night in Washington, D.C. for...
-
May 19, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 16, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases